The TOT-HER3 (a window-of-opportunity study of patritumab deruxtecan, a HER3 directed ADC in operable breast cancer according to ERBB3 expression) trial is designed to assess whether a single dose of patritumab deruxtecan can increase immune infiltration and the lysis of tumor cells during short-term preoperative treatment in hormone receptor (HR)-positive/HER2-negative primary breast cancer. This evidence concerns the gene ERBB2 and neoplasm.